Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779472 | 1.00 | OPRM1 (0.35) | OPRM1DNM1ALDH1A1MEN1KMT2A | |
| SCHEMBL22096786 | 1.00 | OPRM1 (0.35) | OPRM1DNM1ALDH1A1MEN1KMT2A | |
| SCHEMBL21883562 | 1.00 | OPRM1 (0.35) | OPRM1DNM1ALDH1A1MEN1KMT2A | |
| SCHEMBL19251213 | 0.80 | GNAI3 (0.40) | OPRM1DNM1FDPSSPHK1LMNA | |
| SCHEMBL26891861 | 0.79 | NCF1 (0.38) | ALDH1A1KMT2A | |
| SCHEMBL24555502 | 0.78 | EBP (0.38) | OPRM1DNM1TSHRFDPSLMNA | |
| SCHEMBL23733438 | 0.78 | EBP (0.38) | OPRM1DNM1TSHRFDPSLMNA | |
| SCHEMBL23733443 | 0.78 | EBP (0.38) | OPRM1DNM1TSHRFDPSLMNA | |
| SCHEMBL21883555 | 0.77 | NCF1 (0.34) | ALDH1A1TDP1 | |
| SCHEMBL23491205 | 0.77 | GNAI3 (0.36) | FDPSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | OPRM1 467/4885DNM1 1505/4885ALDH1A1 4626/4885 |
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | OPRM1 467/4885DNM1 1505/4885ALDH1A1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.